Healthcare & Pharmaceuticalscategory US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug June 17, 2024 Reuters, the news and media division of Thomson Reuters, ...

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The company’s shares opened today at $121.40. According to ...

Germany’s BioNTech has said it has not received any takeover approaches after it began a high-profile coronavirus vaccine trial with Pfizer in Germany, following press reports over the weekend.

The BioNTech SE ADR BNTX slid 2.69% to $112.51 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and the ...

Pfizer Inc. and BioNTech SE said Friday that a Phase 3 trial of their COVID-19-influenza combination vaccine candidate met one of its two objectives. The trial’s two primary objectives were for ...

The Food and Drug Administration approved an updated coronavirus vaccine manufactured by Novavax Friday, days after new mRNA coronavirus vaccines manufactured by Pfizer-BioNTech and Moderna ...

Users on X reported the change early on Friday, noting that the Facebook app's logo on their mobile devices — typically a white F on a blue background — had changed to a blue F on a black ...

GDANSK, Aug 19 (Reuters) - BioNTech (22UAy.DE), opens new tab on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $171.00. John Newman has given his Buy ...

The Food and Drug Administration has greenlighted three updated vaccines — the Pfizer-BioNTech and Moderna shots, and now a third one from Novavax, which was just authorized by the FDA on Friday.

BioNTech SE Sponsored ADR (BNTX) shares soared 5.8% in the last trading session to close at $105. The move was backed by solid volume with far more shares changing hands than in a normal session.

BioNTech (NASDAQ:BNTX) announced Tuesday that its mRNA-based cancer therapy BNT111, in combination with Regeneron’s ...